Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | May 6, 2024 |
| Target | Modern Meadow - Beauty & Biomedical Division |
| Sector | Life Science |
| Buyer(s) | HTL Biotechnology |
| Sellers(s) | Modern Meadow |
| Deal Type | Divestiture |
FILTER BY
HTL Biotechnology is a fast-growing biotech and industrial firm leading the development and production of innovative pharmaceutical-grade biopolymers. The company has developed a state-of-the-art biopolymers platform that provides customized, pharmaceutical-grade biopolymer solutions to leading pharmaceutical and medical device companies worldwide. Its products are used in therapeutic areas such as ophthalmology, rheumatology, urology, dermatology, and medical aesthetics. HTL Biotechnology was formed in 1992 and is based in Javene, France.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| State: New Jersey | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2024 | 1 of 1 |
Modern Meadow is a provider in bio fabrication that involves the design of cells to produce and assemble collagen and other proteins to yield leather that is “biologically identical” to traditional types. Modern Meadow was founded in 2011 and is based in Nutley New Jersey.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| State: New Jersey | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2024 | 1 of 1 |
